Aerosolised prostacyclin for pulmonary hypertension in neonates

L Bindl, H Fahrenstich, U Peukert

Abstract
Aerosolised prostacyclin (PGI₂) was administered to two neonates with pulmonary hypertension to dilate the pulmonary vessels selectively. The alveolar-arterial oxygen gradient fell from 73-2 (patient 1) and 71.8 kPa (patient 2) to 33-8 and 26.7 kPa respectively. Systemic blood pressure remained stable while pulmonary blood pressure declined in patient 1. When inhaled, PGI₂ seems to improve oxygenation, mainly due to reduction of intrapulmonary shunting.

(Arch Dis Child 1994; 71: F214–F216)

The intravenous use of vasodilatory drugs in the treatment of pulmonary hypertension is limited by an attendant drop in systemic vascular resistance. Furthermore, intrapulmonary shunting may be enhanced. Interest has therefore been focused on the inhalation of nitric oxide. It induces selective pulmonary vasodilation in persistent pulmonary hypertension of the neonate and in pulmonary hypertensive crisis after repair of cardiac malformations.

It has been shown that the inhalation of prostacyclin (PGI₂) reverses the pulmonary vasoconstriction in hypoxic dogs to a similar degree to nitric oxide. Recently its effective use in patients with adult respiratory distress syndrome has been reported. We describe the effect of nebulised PGI₂ in two neonates with pulmonary hypertension.

Methods
Pulmonary hypertension was diagnosed by continuous wave Doppler. Systolic pulmonary blood pressure was calculated as the sum of central venous pressure and the gradient between right ventricle and right atrium measured by continuous wave Doppler. Tricuspid regurgitation was present in both patients; there was no pulmonary stenosis. Systemic blood pressure was measured via an umbilical arterial line in patient 1 and an arterial line in the left radial artery in patient 2. Alveolar-arterial oxygen difference (AaDO₂) was calculated by the simplified formula:

\[ \text{AaDO}_2 \text{ (mm Hg)} = \frac{\text{FiO}_2 \times (\text{barometric pressure} - 6 \times 3 \text{kPa}) - \text{Paco}_2 - \text{Pao}_2}{\text{FiO}_2} \]

(where \(\text{FiO}_2\) = fractional inspired oxygen, \(\text{Paco}_2\) = arterial carbon dioxide tension, \(\text{Pao}_2\) = arterial oxygen tension).

In both patients a time cycled, pressure limited, continuous flow infant ventilator was used. After parental consent was obtained, aerosolised PGI₂ was applied over a period of 45 minutes. Ventilator settings were constant and the transcutaneous measurements of oxygen tension and carbon dioxide tension remained stable for one hour before administration of PGI₂. We used a SPAG-2 nebuliser, generating an aerosol with a mean particle diameter of 1.3 μm. The nebuliser was driven by an air oxygen mixture with an FiO₂ equal to the ventilator gas at a pressure of 179 kPa. The ventilator gas flow (8 l/min) was reduced according to the amount of nebuliser flow (5 l/min). FiO₂, peak inspiratory pressure, and mean arterial pressure remained unchanged. The PGI₂ solution in glycine buffer contained 2.5 mg PGI₂/ml and was delivered at a rate of 6 ml/hour to the ventilator circuit next to the tracheal tube connector. The dose of aerosolised PGI₂ that passed the endotracheal tube was calculated as follows:

\[ \text{PGI}_2 \text{ (ng/kg/min)} = 250 T_i/(T_i+T_e)/\text{body weight (kg)} \]

\((T_i=\text{the inspiratory and } T_e=\text{the expiratory time})\).

FiO₂ was reduced when the oxygen saturation exceeded 95%.

Case reports
CASE 1
A boy, weighing 4080 g (large for gestational age), was born at 35 weeks' gestation and delivered spontaneously to an obese non-diabetic 31 year old mother (gravida 2, para 2). His Apgar scores were 6 and 9 at one and five minutes respectively. The amniotic fluid was clear. There were no clinical or laboratory signs of infection. At 6 hours of age, nasal continuous positive airway pressure with an FiO₂ of 0.3 was initiated owing to increasing respiratory distress (respiratory rate 80 breaths/min, PaO₂ 4.67 kPa, PaCO₂ 7.86 kPa, pH 7.20). At 20 hours of age, mechanical ventilation had to be established because of increased oxygen demand. A chest radiograph was normal except for slight generalised opacification. Pulmonary hypertension was diagnosed. Atrial shunting, predominantly right to left, was detected by colour Doppler. At 48 hours of age the AaDO₂ was 73.2 kPa, PaCO₂ 6.00 kPa, and pH 7.37. The patient was ventilated at a rate of 60 breaths/min with a flow of 8 l/min, an inspiratory to expiratory ratio of 1.2 and an inspiratory pressure of 28/3 cm H₂O at onset. The dose of aerosolised PGI₂ was 20 ng/kg/min. Oxygenation improved (figure); there was a slight decrease in pulmonary arterial pressure (table); atrial
Aerosolised prostacyclin for pulmonary hypertension in neonates

Effect on pulmonary arterial pressure. Thirty minutes after the end of the inhalative administration of PGI2, the drug was infused intravenously at a rate of 11 ng/kg/min over 24 hours with only slight effect on oxygen saturation. Pulmonary arterial pressure hypertension had disappeared, the chest radiograph showed a better expansion of the right lung. The child was extubated after 16 days on the ventilator.

Discussion

Treatment of pulmonary hypertension in the neonate aims to reduce pulmonary vascular resistance while maintaining systemic resistance. Alkalisation is the mainstay of treatment. Intravenous administration of vasodilatory drugs is accompanied by a concomitant fall in systemic vascular resistance, which may also entail persistent right to left shunting and arterial hypotension. Furthermore, in patients with impaired alveolar ventilation, a reversal in hypoxic pulmonary vasoconstriction may increase perfusion of poorly ventilated regions, leading to arterial desaturation. The reports on the first clinical experiences using nitric oxide in patients of all age groups demonstrated that local pulmonary vasodilation can be achieved by inhalation of a short lived vasodilator drug. In adults with respiratory distress syndrome, inhaled nitric oxide not only improved pulmonary hypertension but also decreased intrapulmonary shunting, whereas the infusion of PGI2 led to arterial desaturation.

Inhalation of PGI2 at a rate of 0.87 ng/kg/min in dogs reversed hypoxic pulmonary vasoconstriction. A solution of 0.43 µg PGI2/ml was aerosolised by a jet nebuliser to particles with a diameter of <2 µm. The use of nebulised PGI2 in man was first reported by Hardy et al who administered up to 1000 ng/kg/min in asthma patients. The use of PGI2 aerosol with a mean particle diameter of 2.7 µm in three patients with adult respiratory distress syndrome produced a clinically relevant reduction in intrapulmonary shunting. The calculated dose was 17–50 ng/kg/min. A 20% reduction in pulmonary arterial pressure without a significant reduction in systemic blood pressure was achieved. In our patients AaDo2 decreased dramatically; pulmonary arterial pressure fell slightly in patient 1 and was not substantially reduced in patient 2. In patient 2 the persistence of pulmonary hypertension, which had also not been reduced by intravenous PGI2, may have been due to the poor expansion of the right lung. The dose of nebulised PGI2 was in the same range as in the study of Walmrath and colleagues. When it reached the alveolar region, however, the dose was effectively smaller as there is a proportionally larger dead space in newborn infants.

We did not observe any drop in systemic blood pressure. The improved oxygenation can be explained mainly by a reduction of ventilation perfusion mismatching, because only a slight reduction of the pulmonary-to-systemic pressure ratio occurred in patient 1 and suprasystemic pressure persisted in

### Changes in AaDo2 during inhalation (start A, end B) of PGI2

![Graph showing changes in AaDo2](image)

- Patient 1
- Patient 2

<table>
<thead>
<tr>
<th>Time (min)</th>
<th>-30</th>
<th>+30</th>
<th>+60</th>
</tr>
</thead>
<tbody>
<tr>
<td>pH</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Case 1</td>
<td>7.42</td>
<td>7.36</td>
<td>7.37</td>
</tr>
<tr>
<td>Case 2</td>
<td>7.38</td>
<td>7.35</td>
<td>7.33</td>
</tr>
<tr>
<td>Systolic/diastolic pressure (mm Hg)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Case 1</td>
<td>53/31</td>
<td>66/39</td>
<td>68/35</td>
</tr>
<tr>
<td>Case 2</td>
<td>62/39</td>
<td>63/32</td>
<td>57/33</td>
</tr>
<tr>
<td>Pulmonary arterial pressure (mm Hg)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Case 1</td>
<td>47</td>
<td>37</td>
<td>-</td>
</tr>
<tr>
<td>Case 2</td>
<td>86</td>
<td>81</td>
<td>-</td>
</tr>
</tbody>
</table>

Arterial pH, systemic systolic and diastolic blood pressure and systolic pulmonary arterial pressure 30 minutes before, 30 minutes after, and 15 minutes after the end of PGI2 inhalation
Hydrops fetalis caused by a blood group antibody usually undetected in routine screening

J Smoleniec, N Anderson, G Poole

Abstract
A case of isoimmunisation in pregnancy caused by antibodies to the Kp\textsuperscript{a} red blood cell antigen is described. The preceding pregnancy had resulted in fetal hydrops for which no cause was found as the antibody screening cells used to investigate the fetal hydrops were Kp\textsuperscript{a} negative. This case emphasises the importance of serological screening at a reference laboratory for low frequency red cell antigens before a diagnosis of non-immune hydrops is made.

(Arch Dis Child 1994; 71: F216–F217)

The Penny (Kp\textsuperscript{a}) and Rautenberg (Kp\textsuperscript{b}) antigens are part of the Kell blood group system. The incidence of Kp\textsuperscript{a} is 2% in the white population.\textsuperscript{1} Anti-Kp\textsuperscript{a} is known to cause haemolytic disease of the newborn but is not usually associated with hydrops fetalis or haemolysis severe enough to require intrauterine transfusion.\textsuperscript{2}

Case report
The serum of a 33 year old woman in her fourth pregnancy was found to contain anti-Kp\textsuperscript{a} (Penny) during her routine antenatal serologcal screening at 17 weeks' gestation. Her first pregnancy seven years previously resulted in a normal vaginal delivery. Five years later she had a spontaneous abortion at 7 weeks' gestation. In the third pregnancy, intrauterine death of the fetus occurred at 17 weeks' gestation. The fetus was hydropic but no fetal cells were obtained for red cell grouping or antibody identification. No irregular antibodies were found in the maternal serum, and no other cause for the hydrops was identified. She had no history of previous blood transfusion.

Her red cells were phenotyped as group A Rh D positive, Kp(a—b—). Her husband's red cells were phenotyped as group O Rh D positive, Kp(a+b+); being heterozygous for the Kp\textsuperscript{a} antigen, and therefore giving the baby a 50% chance of being Kp\textsuperscript{a} positive. The titre of anti-Kp\textsuperscript{a} was 256 at 17 weeks' gestation, and conservative management was advised with weekly ultrasound scanning for fetal hydrops and maternal blood sampling every two weeks. At 24 weeks' gestation the titre of anti-Kp\textsuperscript{a} had risen to 1000 and at 25 weeks, early fetal ascites was noted by ultrasound scanning. Intravenous fetal blood sampling revealed a severely anaemic fetus with a haemoglobin concentration of 40 g/l. The direct Coombs test (direct antiglobulin test) was positive and the fetal cells were typed as group O Rh D positive, Kp(a+b+). Spectrophotometric measurement of the deviation in optical density of the amniotic fluid at 450 nm (A450) was unhelpful in predicting the severity of the fetal anaemia.

The pregnancy was managed with regular intrauterine transfusions up to 32 weeks'
Aerosolised prostacyclin for pulmonary hypertension in neonates.

L Bindl, H Fahnenstich and U Peukert

Arch Dis Child Fetal Neonatal Ed 1994 71: F214-F216
doi: 10.1136/fn.71.3.F214

Updated information and services can be found at:
http://fn.bmj.com/content/71/3/F214

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/